Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010

GBI Research, November 2011, Pages: 230

Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010

Summary

GBI Research, the leading business intelligence provider, has released its latest research “Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010”, which provides insights into CNS disorder therapeutics market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the major CNS disorder including Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, diabetic neuropathy, major depressive disorder (MDD), bipolar disorder, schizophrenia insomnia, epilepsy, attention deficit hyperactivity disorder (ADHD) and migraine. The report also provides the share of generics in global CNS disorder therapeutics market as well as in each indication market. The report examines the global CNS disorder treatment usage patterns. In addition, the geographical distribution of CNS disorder and market across the US, the top five countries of Europe and in Japan. The report also includes insights into the CNS disorder R&D product pipeline and explores the competitive landscape including major players in CNS disease market. Finally, the report also includes analysis on Mergers and Acquisitions (M&As) and licensing agreements that took place in CNS disorder therapeutics market.

GBI Research analysis shows that the overall global CNS disorder therapeutics market for the eleven indications that includes Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, diabetic neuropathy, major depressive disorder (MDD),bipolar disorder, schizophrenia insomnia, epilepsy, attention deficit hyperactivity disorder (ADHD) and migraine. valued as $53.1 billion in 2010 that grew from $36.8 billion in 2002 indicating a CAGR of 4.7% The market is expected to witness a fluctuation in a view of patent expiries followed by generic erosion and possible launch of novel molecules. The market is expected to witness a comparatively slow growth at a CAGR of 1.4% between 2010 and 2017 and is estimated to reach $58.6 billion in 2017. Rising geriatric population all over the world, increased life expectancy along with anticipated launch of novel molecules will drive the growth of CNS disease market in future. The market for Alzheimer's disease and multiple sclerosis is expected to witness a significant growth due to expected launch of promising molecules with disease modifying characteristic and novel mechanism of action. Patent expiries of drugs in recent and upcoming years is the only barrier to global CNS disorder therapeutics market however expected launch of novel molecules with disease modifying characteristic and better safety and efficacy will drive the market in forecast period.

Scope

- Data and analysis on the CNS disorder therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the CNS disorder therapeutics market from 2002 to 2010, with forecasts to 2017.
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- Share of the generics in global CNS disorder therapeutics market and for the market of each indication that is covered in the report.
- Key drivers and restraints that have had a significant impact on the market.
- The competitive landscape of the global CNS disorder therapeutics market including top companies benchmarking. The key companies studied in this report are Eli Lilly, Pfizer, AstraZeneca, Teva, and Johnson & Johnson.
- Key M&A activities and Licensing Agreements that took place in 2009 and 2010 in the CNS disease market.

Reasons to buy

- Align your product portfolio to the markets with high growth potential.
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Device a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

1
1 4
1.1 List of Tables 8
1.2 List of Figures 12
2 CNS Disorder Therapeutic Market to 2017 - Introduction 15
2.1 GBI Research Report Guidance 15
3 CNS Disorder Therapeutic Market to 2017 - Global Market Overview 16
3.1 Introduction 16
3.2 Revenue 17
3.2.1 Generic Share 18
3.2.2 Annual Cost of Treatment 19
3.3 Top CNS Drug Products 20
3.3.1 Seroquel (IR/XR) (quetiapine fumarate) 20
3.3.2 Zyprexa (olanzapine) 20
3.3.3 Cymbalta (duloxetine Hcl) 21
3.3.4 Copaxone (glatiramer acetate) 21
3.3.5 Lyrica (pregabalin) 22
3.3.6 Abilify (aripiprazole) 22
3.3.7 Avonex (Interferon beta-1a) 23
3.3.8 Rebif (interferon beta-1a) 23
3.3.9 Effexor (venlafaxine) 23
3.3.10 Betaferon /Betaseron (Interferon beta-1b) 24
4 CNS Disorder Therapeutic Market to 2017 - Geographical Landscape 25
4.1 Revenue Analysis by Geography 25
4.2 The US 26
4.2.1 Revenue 26
4.2.2 Annual Cost of Treatment 27
4.3 Top Five Countries of Europe 28
4.3.1 Revenue 28
4.3.2 Annual Cost of Treatment 30
4.4 Japan 31
4.4.1 Revenue 31
4.4.2 Annual Cost of Treatment 32
5 CNS Disorder Therapeutic Market to 2017 - Therapeutic Landscape 33
5.1 Alzheimer's Disease 33
5.1.1 Introduction 33
5.1.2 Revenue 35
5.1.3 Annual Cost of Treatment 39
5.1.4 Treatment Usage Patterns 40
5.2 Drivers and Restraints to Alzheimer's Disease Market 42
5.2.1 Drivers for Alzheimer's disease Market 42
5.2.2 Restraints for Alzheimer's disease Market 43
5.3 Attention Deficit Hyperactivity Disorder (ADHD) 43
5.3.1 Introduction 43
5.3.2 Revenue 45
5.3.3 Annual Cost of Treatment 49
5.3.4 Treatment Usage Patterns 50
5.4 Drivers and Barriers to ADHD Market 52
5.4.1 Drivers for ADHD Market 52
5.4.2 Barriers for ADHD Market 52
5.5 Bipolar Disorder 53
5.5.1 Introduction 53
5.5.2 Revenue 55
5.5.3 Annual Cost of Treatment 58
5.5.4 Treatment Usage Patterns 59
5.6 Drivers and Barriers to Bipolar Disorder Market 61
5.6.1 Drivers for Bipolar Disorder Market 61
5.6.2 Barriers for Bipolar Disorder Market 61
5.7 Diabetic Neuropathy 62
5.7.1 Introduction 62
5.7.2 Revenue 64
5.7.3 Annual Cost of Treatment 67
5.7.4 Treatment Usage Pattern 68
5.8 Drivers and Restraints to Diabetic Neuropathy Market 70
5.8.1 Drivers for Diabetic Neuropathy Market 70
5.8.2 Restraints for the Diabetic Neuropathy Therapeutics Market 70
5.9 Epilepsy 71
5.9.1 Introduction 71
5.9.2 Revenue 72
5.9.3 Annual Cost of Treatment 75
5.9.4 Treatment Usage Patterns 76
5.10 Drivers and Barriers to Epilepsy Market 78
5.10.1 Drivers for Epilepsy Market 78
5.10.2 Barriers to Epilepsy Market 78
5.11 Insomnia 79
5.11.1 Introduction 79
5.11.2 Revenue 81
5.11.3 Annual Cost of Treatment 84
5.11.4 Treatment Usage Patterns 85
5.12 Drivers and Barriers to Insomnia Market 87
5.12.1 Drivers for Insomnia Market 87
5.12.2 Barriers for Insomnia Market 88
5.13 Migraine 88
5.13.1 Introduction 88
5.13.2 Revenue 90
5.13.3 Annual Cost of Treatment 94
5.13.4 Treatment Usage Patterns 95
5.14 Drivers and Barriers for Migraine Market 98
5.14.1 Drivers for Migraine Market 98
5.14.2 Barriers for Migraine Market 99
5.15 Multiple Sclerosis 99
5.15.1 Introduction 99
5.15.2 Revenue 102
5.15.3 Annual Cost of Treatment 106
5.15.4 Treatment Usage Patterns 107
5.16 Drivers and Restraints to Multiple Sclerosis Therapeutics Market 109
5.16.1 Drivers for Multiple Sclerosis Market 109
5.16.2 Restraints for Multiple Sclerosis Market 110
5.17 Parkinson’s Disease 110
5.17.1 Introduction 110
5.17.2 Revenue 112
5.17.3 Annual Cost of Treatment 115
5.17.4 Treatment Usage Patterns 116
5.18 Drivers and Restraints to Parkinson’s Disease Therapeutics Market 118
5.18.1 Drivers for the Parkinson’s disease Therapeutics Market 118
5.18.2 Restraints for the Parkinson’s disease Therapeutics Market 118
5.19 Schizophrenia 119
5.19.1 Introduction 119
5.19.2 Revenue 121
5.19.3 Annual Cost of Treatment 124
5.19.4 Treatment Usage Pattern 125
5.20 Drivers and Barriers to Schizophrenia Market 127
5.20.1 Drivers for Schizophrenia Market 127
5.20.2 Barriers for Schizophrenia Market 128
5.21 Major Depressive Disorder (MDD) 128
5.21.1 Introduction 128
5.21.2 Revenue 130
5.21.3 Annual Cost of Treatment 133
5.21.4 Treatment Usage Patterns 134
5.22 Drivers and Barriers to MDD Market 136
5.22.1 Drivers for MDD Market 136
5.22.2 Barriers for MDD Market 136
6 Central Nervous System Disorders Therapeutics Market to 2017 - Product Pipeline Analysis 138
6.1 Introduction 138
6.1.1 Product Pipeline by Indication 138
6.1.2 Product Pipeline by Clinical Stage of Development 139
6.2 Alzheimer's disease 140
6.2.1 Introduction 140
6.3 Attention Deficit Hyperactivity Disorder (ADHD) 150
6.3.1 Introduction 150
6.4 Bipolar Disorder 153
6.4.1 Introduction 153
6.5 Diabetic Neuropathy 155
6.5.1 Introduction 155
6.6 Epilepsy 157
6.6.1 Introduction 157
6.7 Insomnia 161
6.7.1 Introduction 161
6.8 Major Depressive Disorder (MDD) 163
6.8.1 Introduction 163
6.9 Migraine 167
6.9.1 Introduction 167
6.10 Multiple Sclerosis 169
6.10.1 Introduction 169
6.11 Parkinson's Disease 175
6.11.1 Introduction 175
6.12 Schizophrenia 182
6.12.1 Introduction 182
6.13 NDA Filed Molecules 186
6.13.1 Alzheimer's disease 186
6.13.2 Bipolar Disorder 187
6.13.3 Epilepsy 189
6.13.4 Insomnia 191
6.13.5 MDD 193
6.13.6 Migraine 194
6.13.7 Parkinson’s disease 195
6.13.8 Multiple sclerosis 195
7 CNS Disorder Therapeutic Market to 2017 - Competitive Landscape 198
7.1 Market Share Analysis 198
7.1.1 Eli Lilly 199
7.1.2 Pfizer 200
7.1.3 AstraZeneca 201
7.1.4 Johnson & Johnson (J&J) 202
7.1.5 Teva 203
8 CNS Disorder Therapeutic Market to 2017 - M&A Landscape 204
8.1 M&A Deals (2010-2011) 204
8.1.1 M&A Deals by Region 204
8.1.2 M&A Deals by Indication 205
8.1.3 M&A Deals by Value 206
8.1.4 Deal Summary of M&A Deals by Value 209
8.2 Licensing Deals 212
8.2.1 Deal Summary 216
8.3 Co-development Deals 218
8.3.1 Deal Summary 220
9 CNS Disorder Therapeutic Market to 2017 - Appendix 223
9.1 Market Definitions 223
9.2 Abbreviations 223
9.3 Research Methodology 224
9.3.1 Coverage 224
9.3.2 Secondary Research 225
9.3.3 Primary Research 225
9.3.4 Therapeutic Landscape 226
9.3.5 Geographical Landscape 229
9.3.6 Pipeline Analysis 229
9.3.7 Competitive Landscape 229
9.3.8 Expert Panel Validation 229
9.4 Contact Us 229
9.5 Disclaimer 229
9.6 Sources 230

GBI Research, the leading business intelligence provider, has released its latest research “Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010”, which provides insights into CNS disorder therapeutics market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the major CNS disorder including Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, diabetic neuropathy, major depressive disorder (MDD), bipolar disorder, schizophrenia insomnia, epilepsy, attention deficit hyperactivity disorder (ADHD) and migraine. The report also provides the share of generics in global CNS disorder therapeutics market as well as in each indication market. The report examines the global CNS disorder treatment usage patterns. In addition, the geographical distribution of CNS disorder and market across the US, the top five countries of Europe and in Japan. The report also includes insights into the CNS disorder R&D product pipeline and explores the competitive landscape including major players in CNS disease market. Finally, the report also includes analysis on Mergers and Acquisitions (M&As) and licensing agreements that took place in CNS disorder therapeutics market.

Anticipated Launch of Novel Molecules Will Drive Growth of the CNS Disease Market in Forecast Period

The global central nervous system (CNS) disorder therapeutics market is valued as $53.1 billion in 2010, grew from $36.8 billion in 2002 with a Compound Annual Growth Rate (CAGR) of 4.7%. Increasing geriatric populations all over the world along with increases in life expectancy are expected to increase the disease population of CNS disorders.

CNS Disorder Therapeutic Market, Global, Revenue Forecast ($bn), 2002-2017

Source: GBI Research, RXUSA, ZenRx, MedScape, Company Annual Reports, FDA, Pharmaceuticals and Medical Devices Agency (PMDA), European Medicines Agency (EMEA),Orange book, JAPIC

The product pipeline of the CNS disorder therapeutics market is promising, with many novel molecules at various stages of development, some with disease-modifying characteristics. The anticipated launch of late stage and novel molecules is expected to fulfill the unmet needs and drive the growth of the global CNS disorders therapeutics market in upcoming years. The product pipeline for multiple sclerosis (MS) has many orally administered novel molecules, and for Alzheimer’s disease the product pipeline has novel molecules such as bapineuzumab, solanezumab and BMS-708163 which target the underlying causes of the disease and thus may offer significant clinical benefits to the patients. The market for schizophrenia and bipolar disorder therapeutics is estimated to be driven by the anticipated launch of AZ-004 and other molecules such as cariprazine, zicronapine, and RG-1678 and aripiprazole depot injection. The continued uptake of non stimulants and anticipated launch of pipeline molecules is expected to have a significant impact on the ADHD therapeutics market. In the next few years the market will witness patent expiries of major drugs, however, the rapid uptake of new molecules is expected to stabilize the market’s decline and the market is expected to grow with a CAGR of 1.4% from 2010 to 2017 to reach $58.6 billion in 2017.

Eli Lilly
Pfizer
AstraZeneca
Johnson & Johnson (J&J)
Teva

Customers who bought this item also bought

• CNS Therapeutics - Global Strategic Business Report
• Clinical Trial Recruitment in Central Nervous System Disorders - Highest Number of Patients were Recruited for Clinical Trials in Schizophrenia
• Posttraumatic Stress Disorder Therapeutics (PTSD) - Pipeline Assessment and Market Forecasts to 2019
• Guide to U.S. Specialty Pharmaceutical Market: Companies, Products and Market Data
• Gastrointestinal Disorder Therapeutics Market to 2017 - Crohn's Disease and Irritable Bowel Syndrome Markets Show Strongest Growth
• Global Attention Deficit Hyperactivity Disorder Epidemiology and Patient Flow Analysis - 2012
• Global Bipolar Disorder Epidemiology and Patient Flow Analysis - 2012
• Obsessive Compulsive Disorder (OCD) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
• Bipolar Disorder - Global Strategic Business Report
• Pediatric Drugs and Vaccines - Global Business Strategic Report